-

Investing in Future Scientists, Feinstein Institutes Gets $1.5M NIH Grant to Develop Training Program

original Anne Davidson, MBBS, professor in the Institute of Molecular Medicine at the Feinstein Institutes for Medical Research. (Credit: Northwell Health)

Anne Davidson, MBBS, professor in the Institute of Molecular Medicine at the Feinstein Institutes for Medical Research. (Credit: Northwell Health)

MANHASSET, N.Y.--(BUSINESS WIRE)--Doubling down on efforts to prepare highly qualified young scientists for a career in immune disease-focused medical research, The Feinstein Institutes for Medical Research, the science arm of Northwell Health, has been awarded a multi-year National Institutes for Health (NIH) grant totaling $1.5 million. The grant will support the development of a rigorous training program in translational immunology for two pre-doctoral and one post-doctoral candidates in the Institute of Molecular Medicine at the Feinstein Institutes.

The program will operate in conjunction with the Elmezzi Graduate School of Molecular Medicine and the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.

As one of the top 6 percent of independent research institutions funded by the NIH, the Feinstein Institutes is a trailblazer in basic science research, particularly the immune system’s role in multiple diseases. The Institute of Molecular Medicine is ideally positioned to train future physician-scientists through its close relationships and collaborations between physicians, clinical researchers and basic science researchers across the health system.

“Highly trained scientists are needed to help propel the advances of biomedical research which will result in better care for patients with immunologic and inflammatory disorders,” said Anne Davidson, MBBS, professor in the Institute of Molecular Medicine at the Feinstein Institutes, and program lead. “Through the support of the NIH we are investing in the future of our science, and specifically in smart, dedicated young investigators who may one day help cure some of the most serious diseases.”

The Feinstein Institutes has two major non-federally funded training programs; the first with the Elmezzi Graduate School of Molecular Medicine to confer a doctorate in Molecular Medicine to exceptional, recently graduated physicians with interest in translational research. The second is with the Donald and Barbara Zucker School of Medicine, recognized among the top medical schools nationwide for medical research and primary care. With these two training programs, there is already a strong infrastructure in place to help prepare these young investigators.

“Scientific advancements require training up-and-coming scientists,” said Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes. “Now the NIH’s support of Dr. Davidson’s program will strengthen the foundation for training future leaders in the science of autoimmune disease.”

The Feinstein Institutes continues to receive significant extramural funding, including a recent $1.3 million NIH grant to study neuro-immune signaling for bioelectronic medicine research and a $2.9 million NIH grant to investigate in-vitro fertilization genetic risk factors.

About the Feinstein Institutes
The Feinstein Institutes for Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health system science, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how we produce knowledge to cure disease, visit http://feinstein.northwell.edu and follow us on LinkedIn.

Contacts

Matthew Libassi
631-793-5325
mlibassi@northwell.edu

Industry:

Feinstein Institutes for Medical Research

Release Versions
English

Contacts

Matthew Libassi
631-793-5325
mlibassi@northwell.edu

More News From Feinstein Institutes for Medical Research

Northwell to Launch Long Island’s First Pancreas Transplant Program

MANHASSET, N.Y.--(BUSINESS WIRE)--Northwell Health has received approval to launch Long Island’s first adult pancreas transplant program, according to a letter from the New York State Department of Health (DOH). The Northwell Transplant Institute at North Shore University Hospital (NSUH) recently hosted a site visit with DOH officials, the final hurdle before opening the program to new patients. Northwell’s pancreas program will open access to patients across the greater New York and southern C...

32BJ Health Fund and Northwell Direct Announce Largest Direct Healthcare Contract of its Kind in the Country, Delivering Major Savings and Expanding Access to Care

NEW YORK--(BUSINESS WIRE)--32BJ Health Fund, the union health fund representing 100,000 building service workers in the New York metro area, and Northwell Direct, a direct-to-employer health care network that partners directly with employers and labor unions to provide health benefits solutions to their employees, today announced a historic deal that will significantly expand access to high-quality care for 32BJ members and their families while delivering dramatic savings to patients, unions an...

Feinstein Institutes’ Researchers Develop Promising Therapeutic for Sepsis-Induced Acute Lung Injury

MANHASSET, N.Y.--(BUSINESS WIRE)--Scientists at Northwell Health’s Feinstein Institutes for Medical Research are making strides in controlling the severe inflammation that is the hallmark of sepsis. This severe condition occurs when the body’s immune system reaction to infection causes it to attack its own tissues and organs, often resulting in organ failure or death. Researchers have uncovered a critical mechanism driving acute lung injury (ALI) in sepsis, identifying a novel subset of neutrop...
Back to Newsroom